Weekly Investment Analysts’ Ratings Changes for Cyclacel Pharmaceuticals (CYCC)

Several brokerages have updated their recommendations and price targets on shares of Cyclacel Pharmaceuticals (NASDAQ: CYCC) in the last few weeks:

• 11/7/2024 – Cyclacel Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 10/30/2024 – Cyclacel Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 10/23/2024 – Cyclacel Pharmaceuticals was downgraded by analysts at Roth Capital from a “strong-buy” rating to a “hold” rating.
• 10/22/2024 – Cyclacel Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 10/14/2024 – Cyclacel Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 10/6/2024 – Cyclacel Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 9/28/2024 – Cyclacel Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 9/20/2024 – Cyclacel Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.

Cyclacel Pharmaceuticals Stock Down 6.7 %

CYCC stock opened at $0.45 on Tuesday. Cyclacel Pharmaceuticals, Inc. has a twelve month low of $0.38 and a twelve month high of $8.66. The company has a market cap of $965,799.00, a P/E ratio of -0.03 and a beta of 0.56. The business’s fifty day moving average is $0.91 and its 200-day moving average is $1.45.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last posted its earnings results on Wednesday, August 14th. The biotechnology company reported ($0.72) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.83) by $0.11. Cyclacel Pharmaceuticals had a negative return on equity of 1,901.11% and a negative net margin of 21,963.75%. During the same quarter last year, the company posted ($6.60) earnings per share. Research analysts anticipate that Cyclacel Pharmaceuticals, Inc. will post -2.29 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cyclacel Pharmaceuticals

A hedge fund recently bought a new stake in Cyclacel Pharmaceuticals stock. Armistice Capital LLC acquired a new position in shares of Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 134,000 shares of the biotechnology company’s stock, valued at approximately $217,000. Armistice Capital LLC owned 9.18% of Cyclacel Pharmaceuticals at the end of the most recent quarter. Institutional investors and hedge funds own 23.58% of the company’s stock.

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.